文献速递前列腺癌

当代前列腺癌淋巴结转移的发病率与结局

Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.
PubMed 文献 · J Urol · 2017-12-26

该研究利用2004至2014年SEER数据,分析前列腺癌各分期的年龄标化发病率趋势,并通过校正Cox比例风险模型评估病变范围对死亡率的影响。结果显示非转移性前列腺癌年发病率下降,而盆腔淋巴结转移发病率上升;盆腔淋巴结转移和远处转移患者的癌症特异性死亡风险显著增加。

要点

  • 非转移性前列腺癌年发病率从5119.1降至2931.9/百万男性(IR 0.57,95%CI 0.56-0.58,p<0.01)。
  • 盆腔淋巴结转移发病率从54.1升至79.5/百万男性(IR 1.47,95%CI 1.33-1.62,p<0.01)。
  • 盆腔淋巴结转移者癌症特异性死亡风险HR 4.5(95%CI 4.2-4.9,p<0.01),远处转移者HR 21.9(95%CI 21.2-22.7,p<0.01)。

核心结论

  • 盆腔淋巴结转移发病率上升,与非转移性前列腺癌检出下降同时发生;这一趋势是否意味着晚期疾病负担增加或仅反映 lead time 缩短尚不清楚,但应密切监测,因为N1疾病增加反映了诊断时不可治愈前列腺癌的增加。

研究设计与样本

  • 基于SEER数据库2004至2014年数据,识别诊断为前列腺癌的男性,分析年龄标化发病率的趋势,并通过校正Cox比例风险分析评估疾病范围对死亡率的影响。

主要发现

  • 非转移性前列腺癌年发病率从5119.1降至2931.9/百万男性(IR 0.57,95%CI 0.56-0.58,p<0.01)。
  • 盆腔淋巴结转移发病率从54.1升至79.5/百万男性(IR 1.47,95%CI 1.33-1.62,p<0.01)。
  • 75岁及以上男性远处转移发病率在2011年较2004年达到最低点(IR 0.81,95%CI 0.74-0.90,p<0.01),2012年较2011年上升(IR 1.13,95%CI 1.02-1.24,p<0.05)。
  • 与非转移性疾病男性相比,盆腔淋巴结转移男性癌症特异性死亡风险显著增加(HR 4.5,95%CI 4.2-4.9,p<0.01),远处转移男性风险显著增加(HR 21.9,95%CI 21.2-22.7,p<0.01)。

关键数值与推荐

  • 非转移性前列腺癌年发病率从5119.1降至2931.9/百万男性(IR 0.57,95%CI 0.56-0.58,p<0.01)。
  • 盆腔淋巴结转移发病率从54.1升至79.5/百万男性(IR 1.47,95%CI 1.33-1.62,p<0.01)。
  • 75岁及以上男性远处转移发病率2011年较2004年最低(IR 0.81,95%CI 0.74-0.90,p<0.01),2012年较2011年上升(IR 1.13,95%CI 1.02-1.24,p<0.05)。
  • 盆腔淋巴结转移者癌症特异性死亡风险HR 4.5(95%CI 4.2-4.9,p<0.01),远处转移者HR 21.9(95%CI 21.2-22.7,p<0.01),均与非转移性疾病男性相比。

临床怎么用

  • 盆腔淋巴结转移发病率上升与非转移性前列腺癌检出下降同时发生,应密切监测,因为N1疾病增加反映了诊断时不可治愈前列腺癌的增加。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The incidence of localized prostate cancer has decreased with shifts in prostate cancer screening. While recent population based studies demonstrated a stable incidence of locoregional prostate cancer, they categorized organ confined, extraprostatic and lymph node positive disease together. However, to our knowledge the contemporary incidence of prostate cancer with pelvic lymph node metastases remains unknown. MATERIALS AND METHODS: We used SEER (Surveillance, Epidemiology and End Results) data from 2004 to 2014 to identify men diagnosed with prostate cancer. We analyzed trends in the age standardized prostate cancer incidence by stage. The impact of disease extent on mortality was assessed by adjusted Cox proportional hazard analysis. RESULTS: During the study period the annual incidence of nonmetastatic prostate cancer decreased from 5,119.1 to 2,931.9 per million men (IR 0.57, 95% CI 0.56-0.58, p <0.01) while the incidence of pelvic lymph node metastases increased from 54.1 to 79.5 per million men (IR 1.47, 95% CI 1.33-1.62, p <0.01). The incidence of distant metastases in men 75 years old or older reached a nadir in 2011 compared to 2004 (IR 0.81, 95% CI 0.74-0.90, p <0.01) and it increased in 2012 compared to 2011 (IR 1.13, 95% CI 1.02-1.24, p <0.05). The risk of cancer specific mortality significantly increased in men diagnosed with pelvic lymph node metastases (HR 4.5, 95% CI 4.2-4.9, p <0.01) and distant metastases (HR 21.9, 95% CI 21.2-22.7, p <0.01) compared to men with nonmetastatic disease. CONCLUSIONS: The incidence of pelvic lymph node metastases is increasing coincident with a decline in the detection of localized disease. Whether this portends an increase in the burden of advanced disease or simply reflects decreased lead time remains unclear. However, this should be monitored closely as the increase in N1 disease reflects an increase in incurable prostate cancer at diagnosis.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bernstein AN, Shoag JE, Golan R, et al. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2017. PMID: 29288121. doi:10.1016/j.juro.2017.12.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。